摘要
目的:观察TP方案联合复方斑蝥胶囊治疗晚期食管癌的临床疗效。方法:将47例晚期食管癌患者按住院号随机分为两组,对照组采用TP方案治疗,治疗组在对照组的基础上加用复方斑蝥胶囊。比较两组患者治疗前后KPS评分、QOL评分、临床疗效及不良反应发生情况。结果:治疗组治疗前后KPS评分和QOL评分差值均高于对照组,两组比较差异有统计学意义(P<0.05);治疗后治疗组缓解率53.85%,对照组缓解率22.73%,两组比较,差异有统计学意义(P<0.05);两组患者Ⅲ、Ⅳ级不良反发生率比较,治疗组均低于对照组,其中胃肠道反应、周围神经毒性和骨髓抑制比较,差异有统计学意义(P<0.05)。结论:TP方案联合复方斑蝥胶囊治疗晚期食管癌可提高临床疗效,改善患者生存质量,降低不良反应发生率。
Objective ： To observe effect of TP scheme combined with compound Mylabris capsule in the treatment of advanced esophageal cancer. Methods ：47 patients with advanced esophageal cancer were randomly divided into two groups. The control group was treated with TP solution. The treatment group was treated with oral compound Mylabris capsule. Then compare KPS and QOL score, clinical curative effect and adverse reactions. Result： The KPS and QOL score of treatment group were significantly greater than that of control group, the difference was statistically significant（P 〈 0.05 ）. The remission rate was 53.85% in treatment group and 22.73% in control group. The difference was statistically significant（P 〈 0.05）. Compared the III and IV degree of adverse reaction rate, the treatment group was significantly less than control group. Compared gastrointestinal tract reaction, peripheral neurotoxicity and bone marrow depression, the difference was statistically significant （P 〈 0.05 ）. Conclusion ： TP scheme combined with compound Mylabris capsule in the treatment of advanced esophageal cancer can improve clinical effect,improve life quality and reduce adverse reactions.
出处
《中医学报》
CAS
2014年第9期1245-1247,共3页
Acta Chinese Medicine
基金
国家自然科学基金项目(编号:30772851)
湖北省卫生厅重点项目(编号:JX2A11)
关键词
晚期食管癌
复方斑蝥胶囊
紫杉醇
顺铂
advanced esophageal cancer
compound Mylabris capsule
Paclitaxel
Cisplatin
